AstraZeneca (AZN) and Daiichi Sankyo (DSNKY) announce positive results from the DESTINY-Breast11 Phase III trial showed Enhertu followed by paclitaxel, trastuzumab and pertuzumab, THP, in the neoadjuvant setting demonstrated a statistically significant and clinically meaningful improvement in the pathologic complete response rate. The trial compared Enhertu followed by THP with dose-dense doxorubicin and cyclophosphamide followed by THP in patients with high-risk, locally advanced HER2-positive early-stage breast cancer. Pathologic complete response is defined as no evidence of invasive cancer cells in the removed breast tissue and lymph nodes following treatment. The secondary endpoint of event-free survival, EFS, was not mature at the time of this analysis; however, an early analysis showed a trend favouring Enhertu followed by THP versus ddAC-THP.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- AstraZeneca, Daiichi Sankyo announce Enhertu demonstrated improvement in IDFS
- AstraZeneca, Daiichi’s Datroway demonstrated significant improvement in OS, PFS
- AstraZeneca announces improvements in pCR rate in DESTINY-Breast11 trial
- AstraZeneca, Daiichi announce ENHERTU showed improvement in IDFS
- Gilead, AstraZeneca, and Roche Data Signal New Growth in Cancer Drug Market